Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 6/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | ACP1 | P24666 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | C1R | P00736 | 1/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4691348 | 0.82 | DHFR (0.41) | DHFRPTPN1TRPA1TRPM8TRPV1 | |
| SCHEMBL4688966 | 0.76 | ADORA2A (0.41) | DHFRADORA3ADORA2AADORA1SLC2A1 | |
| SCHEMBL4687979 | 0.76 | DHFR (0.46) | DHFRPTPN1TRPA1ADORA3ADORA2A | |
| Trifluoroacetic Acid SCHEMBL4691202 | 0.74 | DHFR (0.39) | DHFRADORA2ABACE1 | |
| SCHEMBL5503577 | 0.74 | TRPA1 (0.49) | DHFRPTPN1TRPA1TRPM8TRPV1 | |
| SCHEMBL14256006 | 0.72 | DHFR (0.41) | DHFRSLC2A1 | |
| SCHEMBL27653789 | 0.71 | CYP1A2 (0.43) | DHFRPTPN1TRPA1TRPM8TRPV1 | |
| SCHEMBL4688933 | 0.70 | SLC2A1 (0.40) | PTPN1SLC2A1 | |
| SCHEMBL4689031 | 0.69 | DHFR (0.58) | DHFRADORA2ASLC2A1 | |
| SCHEMBL28759591 | 0.69 | PTPN1 (0.40) | DHFRPTPN1TRPA1TRPM8TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1628979-B1 | DIAMINOPYRROLOQUINAZOLINES COMPOUNDS AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-03-19 | — | — | EP | claimed |
| EP-1628979-B1 | DIAMINOPYRROLOQUINAZOLINES COMPOUNDS AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-03-19 | — | — | EP | disclosed |
| EP-1628979-B1 | DIAMINOPYRROLOQUINAZOLINES COMPOUNDS AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-03-19 | — | — | EP | disclosed |
| US-20070270445-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2007-11-22 | — | — | US | disclosed |
| US-20070270445-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2007-11-22 | — | — | US | disclosed |
| US-7262297-B2 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262297-B2 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2007-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270445-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | PTPN5, DUSP15, PPP5C | DHFR 339/4885PTPN1 9/4885TRPA1 3317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.